Print Programme

Wednesday, 9 October 2019


18:00 -19:00

19:00 - 20:15
Ballroom 3 




20:15 - 22:00


@ lobby outside Ballroom 2 of Mayo Civic Centre

Chair: Kah-Whye Peng
Kah-Whye Peng
, Mayo Clinic Rochester
Welcome to IOVC19
Robert Martuza, Massachusetts General Hospital, Boston, USA
INV01 - Keynote: Tomoki Todo, The University of Tokyo, Japan
Clinical development of oncolytic herpes virus G47Δ

WELCOME RECEPTION: Drinks and Snacks
@ lobby outside Ballroom 2 of Mayo Civic Centre


Thursday, 10 October 2019

08:30  - 10:05

SCIENTIFIC SESSION 1: Virus and Host Interactions / Innate Immunity
Chairs: Grant McFadden
and Martine Lamfers

INV02 - Valery Grdzelishvili, University of North Carolina, Charlotte, USA
Understanding and breaking multiple mechanisms of resistance of pancreatic cancer cells to oncolytic viruses
INV03 - Glen Barber, University of Miami, USA
STING-Dependent Innate Immune Signaling, Viral Oncolysis and Cancer

OR01 - Dimitry M Shayakhmetov, Emory University, USA
Structure-guided engineering of oncolytic adenovirus for systemic cancer therapy
OR02 - T H Hwang, Pusan National University, South Korea
Targeting subtypes of circulating myeloid cells during oncolytic vaccinia virus therapy
OR03, H Nakashima, Brigham and Women's Hospital, USA
In vivo analyses of tumor, immune cells and oncolytic viruses to dissect factors important for efficacy

10:05   - 10:35 COFFEE BREAK
10:35  – 12:30

SCIENTIFIC SESSION 2: Virus and Host Interactions / Adaptive Immunity
Chairs: Tomoki Todo 
and Alan Melcher

INV04 -Jing Qing, Amgen, USA
Mechanisms of OncoVEXmGM-CSF-induced durable and systemic anti-tumor immunity in preclinical models
INV05 - Kevin Harrington, Institute of Cancer Research, London, UK
Pharmacological modulation of oncolytic virotherapy; in search of synthecally lethal combinations

OR04 - M A Muñoz-Alía, Mayo Clinic, Rochester, USA
A CD46-specific measles virus resistant to neutralization by measles-immune human serum
OR05 - Chard Dunmall, Queen Mary University of London, UK
An intravenously injectable oncolytic Vaccinia virus, QM007, demonstrates potent anti-tumor efficacy and sensitises tumors to α-PD1 therapy in murine models of pancreatic cancer
OR06 - T Nakamura, Tottori University, Japan
Tumor-specific replication-competent oncolytic vaccinia virus with stealth effect by engineering viral glycoprotein B5R
OR07 - JS Diallo, Ottawa Hospital Research Institute, Canada
Antibody drug conjugate enhancement of oncolytic virotherapy

12:30  – 13:30 LUNCH BREAK
13:30  – 14:40

SCIENTIFIC SESSION 3: Engineered Viruses
Chairs: John Bell
and Nori Kasahara

INV06 - Liang Deng, Memorial Sloan Kettering Cancer Center, USA
Rational engineering of vaccinia viruses for cancer immunotherapy

OR08 - M G Robertson, University of Minnesota, USA
Clinical translation of adenovirus-based radiotherapy and imaging for pancreatic cancer
OR09 - M BergmanMedical University of Vienna, Austria
Optimization of the oncolytic influenza virus by exchange of the viral hemagglutinin rather than by expression of a T-cell stimulating cytokine
OR10 - K M Budzik, Mayo Clinic, Rochester, USA
Simian Foamy Virus – a New Retroviral Platform for Cancer Gene Therapy

14:40   - 15:10 COFFEE BREAK
15:10   - 16:20

INV07 -Dimitry Zamarin, Memorial Sloan Kettering Cancer Center, USA
Modulation of Newcastle Disease Virus-activated anti-tumor immunity

OR11 - J D Christie, Arizona State University, USA
Exploiting TNF-armed myxoma Virus in a Syngeneic Murine Lung Sarcoma Metastases Model
OR12 - M Yamamoto, University of Minnesota, USA
AdMG-MYOGp(S)-E1-5/3F, MYOG promoter controlled oncolytic adenovirus, selectively kills rhabdomyosarcoma
OR13 - Ahmet Hazini Technische Universität Berlin, Germany
Oncolytic Avirulent Coxsackievirus B3 Strain PD Induces Antitumor Immunity and Prevents Development of Cancer Cachexia

16:20   - 18:00

Chair: Kerry Fisher

Richard Vile (Mayo Clinic)
OVs work better if they encode tumor antigens
vs. Len Seymour (Oxford University)
No they don't

18:30   - 21:00

Dan Abraham Healthy Living Center (6th Floor)
(transport from the venue @18.30)


Friday 11 October 2019

08:30  -  09:50

SCIENTIFIC SESSION 5: Engineered Viruses and cancer vaccines
Chairs: John Beadle 
and Eva Galanis

INV08 Lelia Delamarre, Genenetech  
Harnessing neoantigens for cancer immunotherapy 
INV09 - Autumn Schulze, Mayo Clinic, Rochester, USA
Synthetic Infectious RNA for Oncolytic Virotherapy
OR14 - A L Huff, Mayo Clinic, Rochester, USA
Vesicular stomatitis virus expressing destabilized tumor associated antigens to improve anti-tumor T cell responses
OR15 - D Saha, Texas Tech University, USA
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

09:50   - 10.30 COFFEE BREAK
10:30  -  11:15

SCIENTIFIC SESSION 6: Keynote lecture
Chair: Stephen J Russell

Sponsored by American Society of Gene and Cell Therapy

INV10 - Rosalind Carter, CDC, Atlanta, USA
rVSV Ebola vaccine:  cold chain and logistical challenges for field implementation

11:15  -  12:20

Chair: Stephen J Russell

INV11 - Paola Grandi, Cold Genesys
Treatment of bladder cancer using CG0070
INV12 - Hideki Kasuya, Nagoya University, Japan
Clinical development of Canerpaturev (formerly HF10) as the novel cancer therapy
OR16 - S Naik, Vyriad, USA
Neoadjuvant intravenous oncolytic VSV virotherapy in canines with spontaneous osteosarcoma

12:20   - 13:30 LUNCH
13:30   - 15:45

SCIENTIFIC SESSION 8: Engineered Viruses
Chair: Frank Tufaro
and Brian Champion

INV13 - Chae Ok Yun, Hanyang University, Genemedicine Inc, Seoul, South Korea
Exploring hydrogel system to enhance the therapeutic efficacy of oncolytic adenovirus
INV14 - Grey WilkinsonOncolytics Biotech
Systemic administration of oncolytic reovirus, pelareorep, a metanalysis on the efficiency of tumor delivery
INV15 - Brian Champion, Psioxus Therapeutics, Oxford, UK
Tumor-specific immunogene (T-SIGn) therapy for cancer: preclinical and clinical development of viruses designed to deliver combination immunotherapy locally within the tumor microenvironment
OR17 - A A Szalay, University of Wuerzburg, Germany
Clinical cancer therapy trial: Autologous stem cells as oncolytic vaccine carriers for immunotherapy of cancer in human patients
OR18 - Talian Biran, Oncolys Biopharma, Japan
Final results of Phase 1 dose escalation study of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments
OR19 - Steve Thorne, Western Oncolytics, USA
VET-S3, a next generation clinical oncolytic vaccinia virus
OR20 - E M Kennedy, Oncorus, USA
ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity
OR21 - G Wollmann, University of Innsbruck, Austria
Virotherapy with VSV-GP in a syngeneic lung cancer model is driven by oncolysis rather than antitumor immunity despite strong immune activation in the tumor-micro environment

16.00   - 18:00

Wine and cheese


Saturday 12 October 2019

08:30   - 09:50

SCIENTIFIC SESSION 10:  Personalized OV therapy
Chairs: Brian Lichty
and Samuel Rabkin

INV16 - Martine Lamfers , Erasmus MC Rotterdam, The Netherlands
Development of patient-derived glioblastoma model systems to predict response to OV therapy
INV17 - Eva Galanis, Mayo Clinic, Rochester, USA
Optimizing delivery and personalizing virotherapy treatment;  the measles experience

OR22 - Nicholas Durham, AstraZeneca, USA
Newcastle Disease Virus in Human Derived Tumors: PDX Modeling of Viral Replication and Immune Induction
OR23 - H Lesch, Kuopio Center for Gene and Cell Therapy, Finland
Adherent and suspension platforms for virus production

09:50   - 10:30 COFFEE BREAK
10.30   - 12:30

SCIENTIFIC SESSION 11: GBM focus session and panel discussion
Nino Chiocca and Robert Martuza

INV18 - Nino Chiocca, Brigham and Women’s Hospital, Harvard Medical School, USA
Clinical Trials of Immunovirotherapy in Recurrent Glioblastoma (GBM)
INV19 - Annick Desjardins, Duke University, USA
INV20 - Doug Jolly, Tocagen, Inc, USA
Immune mechanism of action of Toc 511, a retroviral replicating vector, and 5-FC preclinically and clinically
INV21 - Frank Tufaro, DNAtrix, Inc, USA

Panel discussion: 
Chairs: Nino Chiocca and Robert Martuza
Panel members: Annick Desjardins, Frank Tufaro, Doug Jolly, Tomoki Todo

12:30  - 14:00 LUNCH
14.00   - 15:20

SCIENTIFIC SESSION 12: Tumor microenvironment
Chairs: Autumn Schulze
and Sam Rabkin

INV22 - Balveen Kaur, University of Texas Health Science Centre, Houston, USA
PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance
INV23 - Eric Bartee, Medical University of South Carolina, USA
Initiating, maintaining, and augmenting anti-tumor immunity during oncolytic therapy

OR24 - S Warner, Beckman Research Institute, City of Hope, USA
Combination of immune checkpoint inhibition and recombinant orthopoxvirus (CF33-luc) enhances tumor regression despite initially attenuated viral replication"
OR25 - N van Montfoort, Leiden University Medical Center, The Netherlands
Oncolytic reovirus sensitizes immune-silent pancreatic tumors for CD3-bispecific antibody therapy

15.20   - 16:00 COFFEE BREAK
16.00   - 18:30

SCIENTIFIC SESSION 13: Activating the immune system
Chairs: Kah-Whye Peng and Tomoki Todo

INV24 - John Bell, Ottawa Health Research Institute, Canada
Planting bombs inside tumours
INV25 - Gabriella Campadelli-Fiume, University of Bologna, Italy
Second generation retargeted oHSV's primed for checkpoint blocade

Introduction to IOVC2020
Tomoki Todo
, IOVC20 Conference President

19.00   - 23:00

@Landow Atrium in Gonda Building
Conrad Prizes
(courtesy of DNAtrix)
IOVC Travel Awards
Music by: Brian Kinney Band from Minneapolis